Skip to main content

Table 3 Study eligibility and exclusions

From: Hepatic outcomes among adults taking duloxetine: a retrospective cohort study in a US health care claims database

  Duloxetine Venlafaxine SSRI Untreated
N removed N eligible remaining N removed N eligible remaining N removed N eligible remaining N removed N eligible remaining
Member of commercial health insurance plan, with medical coverage and pharmacy benefits, and presence of qualifying eventa during the accrual period   156,682 (100.0 %)   231,793 (100 %)   1,314,147 (100 %)   1,577,784 (100 %)
Baseline exclusions         
 Less than 18 years at index date 1396 155,286 (99.1 %) 2482 229,311 (98.9 %) 33,476 1,280,671 (97.5 %) 60,552 1,517,232 (96.2 %)
 Less than 12 months prior continuous enrollment 79,819 75,467 (48.2 %) 136,147 93,164 (40.2 %) 780,943 499,728 (38.0 %) 791,027 726,205 (46.0 %)
 Prior dispensing of study drug or drug class in the baseline 0 75,467 (48.2 %) 23,753 69,411 (29.9 %) 134,294 365,434 (27.8 %) 334,496 391,709 (24.8 %)
 Had no depression diagnosis in the baseline 27,596 47,871 (30.6 %) 24,844 44,567 (19.2 %) 153,173 212,261 (16.2 %) 0 391,709 (24.8 %)
 Had hepatic injury/chronic hepatic condition in the baseline 10,592 37,279 (23.8 %) 9173 35,394 (15.3 %) 39,354 172,907 (13.2 %) 76,815 314,894 (20.0 %)
 Region affected by Hurricane Katrina 489 36,790 (23.5 %) 509 34,885 (15.1 %) 2020 170,887 (13.0 %) 3556 311,338 (19.7 %)
Cohort assignment based on earliest qualifying index date (pre-propensity score matching) 30,844 (19.7 %) 29,243 (12.6 %) 166,236 (12.6 %) 311,338 (19.7 %)
  1. aInitiation of a study drug, or for untreated patients, a claim for depression associated with a physician visit